Literature DB >> 11704718

Principles of pediatric combination vaccines and practical issues related to use in clinical practice.

M D Decker1.   

Abstract

BACKGROUND: During the past two decades the number of injections that are required per office visit to fulfill the recommended childhood immunization schedule has increased dramatically.
METHODS: By reviewing the literature, the principles associated with pediatric combination vaccines are discussed, and practical issues related to their use in clinical practice are evaluated.
RESULTS: The ideal combination vaccine is safe, effective and easy to store and use, and its antigenic components fit within the recommended immunization schedule. The ideal combination is associated with fewer adverse reactions than the separately administered antigens, with improved efficacy and higher immune responses compared with its component vaccines. An acceptable combination vaccine must provide comparable efficacy and safety to its component vaccines. Although there are a limited number of combination vaccines already available [diphtheria-tetanus-pertussis, inactivated poliovirus vaccine (IPV) and measles-mumps-rubella], effort is being focused on combining these vaccines with other routine vaccines of infancy including Haemophilus influenzae type b (Hib) and hepatitis B vaccine (HepB). Currently under review by the Food and Drug Administration are diphtheria-tetanus-acellular pertussis (DTPa)-HepB-IPV and DTPa-Hib-IPV combination vaccines, and two DTPa-HepB-IPV-Hib vaccines have been licensed in Europe. As more combination vaccines become available, issues such as interchangeability and administration of extra doses are raised; however, it is important not to miss a vaccination opportunity.
CONCLUSIONS: The number of injections required to fulfill the recommended childhood immunization schedule at each visit creates problems for patients and practitioner, sometimes risking a missed opportunity for vaccination. The development of combination vaccines will circumvent this problem and increase compliance and vaccination coverage rates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704718     DOI: 10.1097/00006454-200111001-00002

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

Review 1.  Vaccination greatly reduces disease, disability, death and inequity worldwide.

Authors:  F E Andre; R Booy; H L Bock; J Clemens; S K Datta; T J John; B W Lee; S Lolekha; H Peltola; T A Ruff; M Santosham; H J Schmitt
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

2.  Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts.

Authors:  A Orsi; C Azzari; E Bozzola; G Chiamenti; G Chirico; S Esposito; F Francia; P Lopalco; R Prato; R Russo; A Villani; E Franco
Journal:  J Prev Med Hyg       Date:  2018-06-01

3.  Preferences of healthcare professionals regarding hexavalent pediatric vaccines in Italy: a survey of attitudes and expectations.

Authors:  Giancarlo Icardi; Andrea Orsi; Giovanni Vitali Rosati; Alessia Tognetto; Giovanni Checcucci Lisi; Salvatore Parisi
Journal:  J Prev Med Hyg       Date:  2020-10-06

4.  The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.

Authors:  Sukanta Chatterjee; Sylvan J Rego; Fulton D'Souza; B D Bhatia; Alix Collard; Sanjoy K Datta; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

5.  Combination vaccines.

Authors:  David Ag Skibinski; Barbara C Baudner; Manmohan Singh; Derek T O'Hagan
Journal:  J Glob Infect Dis       Date:  2011-01

6.  Is hepatitis B birth dose vaccine needed in Africa?

Authors:  Cynthia Raissa Tamandjou; Tongai Gibson Maponga; Nafiisah Chotun; Wolfgang Preiser; Monique Ingrid Andersson
Journal:  Pan Afr Med J       Date:  2017-06-22

7.  Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.

Authors:  Manoochehr Karami; Pegah Ameri; Jalal Bathaei; Zeinab Berangi; Tahereh Pashaei; Ali Zahiri; Seyed Mohsen Zahraei; Hussein Erfani; Koen Ponnet
Journal:  BMC Immunol       Date:  2017-08-23       Impact factor: 3.615

8.  DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.

Authors:  Hartono Gunardi; Kusnandi Rusmil; Eddy Fadlyana; Meita Dhamayanti; Rini Sekartini; Rodman Tarigan; Hindra Irawan Satari; Bernie Endyarni Medise; Rini Mulia Sari; Novilia Sjafri Bachtiar; Cissy B Kartasasmita; Sri Rezeki S Hadinegoro
Journal:  BMC Pediatr       Date:  2018-05-28       Impact factor: 2.125

Review 9.  Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology.

Authors:  E Chiappini; C Petrolini; C Caffarelli; M Calvani; F Cardinale; M Duse; A Licari; S Manti; A Martelli; D Minasi; M Miraglia Del Giudice; G B Pajno; C Pietrasanta; L Pugni; M A Tosca; F Mosca; G L Marseglia
Journal:  Ital J Pediatr       Date:  2019-11-19       Impact factor: 2.638

10.  Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access.

Authors:  Tongai G Maponga; Rachel Matteau Matsha; Sébastien Morin; Andrew Scheibe; Tracy Swan; Isabelle Andrieux-Meyer; C Wendy Spearman; Marina B Klein; Jürgen Kurt Rockstroh
Journal:  Hepatol Med Policy       Date:  2017-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.